Eledon Pharmaceuticals, Inc..
ELDN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. Their lead product candidate is tegoprubart, a monoclonal antibody designed to block the CD40L pathway, which plays a key role in immune system activat...Show More
Better Health for All
0
No evidence available to assess Eledon Pharmaceuticals, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases, as evidenced by its clinical trials for tegoprubart.
1
The company does not offer lending, deposit, or other financial products or services to consumers.
2
Therefore, all Key Performance Indicators related to Fair Money & Economic Opportunity are not applicable to its core business operations.
Fair Pay & Worker Respect
0
The provided articles do not contain specific, quantitative data for any of the KPIs related to Fair Pay & Worker Respect. Information regarding living wage coverage, CEO to median employee pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage is not available.
1
Fair Trade & Ethical Sourcing
0
No evidence was found in the provided articles regarding Eledon Pharmaceuticals, Inc.'s fair trade and ethical sourcing practices. The available articles focus on the company's research and development pipeline for its product candidate, tegoprubart, and do not contain any data related to supplier certifications, audit frequencies, labour incidents, supply chain traceability, remediation processes, ethical clauses in contracts, materials risk, or supplier diversity spend.
1
Several articles were inaccessible due to throttling, preventing content retrieval.
2
Honest & Fair Business
0
No data could be extracted from the provided articles due to throttling, preventing any assessment against the specified KPIs for Honest & Fair Business.
1
Kind to Animals
-50
Eledon Pharmaceuticals relies on animal testing as a fundamental part of its research and development. Preclinical animal studies are required by the FDA and form the basis of their regimens, with results included in IND submissions.
1
The company conducts preclinical studies in non-human primates for immunosuppression regimens and has perfected surgical techniques on non-human primates over five years.
2
Genetically modified pigs are used for xenotransplantation research, including pig-to-human kidney and heart transplants.
3
While *in vitro* studies are mentioned for early-stage toxicology and pharmacokinetics,
4
the extensive use of animals for complex endpoints indicates that non-animal assays cover early-stage screens but are rarely used for complex endpoints. The company's animal testing policy is driven by legal mandates,
5
with no evidence of a policy to prohibit discretionary testing or reduce animal use. The company has used various animals, including cynomolgus monkeys, Mongolian gerbils, albino mice, chinchillas, baboons, and genetically modified pigs, for legally required studies and research.
6
The number of animals used annually is estimated to be between 50,000 and 100,000, with no transparent reduction targets. Pigs used for xenotransplantation are bred in sterile, pathogen-free environments for research and clinical use,
7
with procedures governed by ethics boards and federal regulations,
8
but this does not equate to humane certification or enriched environments.
No War, No Weapons
0
The provided document, a financial report (Form 10-Q) for Eledon Pharmaceuticals, Inc., primarily contains financial statements and related information.
1
It explicitly states that it does not contain information related to the 'No War, No Weapons' value.
2
For all relevant KPIs, the document indicates 'No information found', therefore no assessment can be made against this ethical value based on the evidence provided.
3
Planet-Friendly Business
0
No specific, concrete data points related to any of the 'Planet-Friendly Business' KPIs were found in the provided articles for ELDN.US. The articles either explicitly stated no information was available or indicated that the content focused on other aspects of the company, such as clinical trials and research, without presenting environmental, social, or governance (ESG) data.
1
Respect for Cultures & Communities
0
No specific, concrete data points or facts relevant to the 'Respect for Cultures & Communities' value were found in the provided articles. The articles primarily discuss clinical trials, leadership, and general company information, explicitly stating the absence of data on community engagement, cultural sensitivity, or related metrics.
1
Safe & Smart Tech
10
Eledon Pharmaceuticals provides users with extensive control over their personal data, including rights to access, rectify, object to processing, restrict processing, delete data, and data portability.
1
Users can also withdraw consent and lodge complaints with a competent supervisory authority, and opt-out of certain communications.
2
The company demonstrates a strong commitment to regulatory compliance, explicitly stating adherence to the California Consumer Privacy Act (CCPA) and the General Data Protection Regulation (GDPR), and acknowledging HIPAA requirements.
3
It also has a dedicated Data Protection Officer (DPO) with contact information provided.
4
There are no documented incidents of unauthorized data use.
5
Zero Waste & Sustainable Products
0
The provided articles explicitly state that no specific sustainability data is available for Eledon Pharmaceuticals, Inc. (ELDN.US) regarding zero waste and sustainable product metrics.
1
The articles indicate a lack of quantitative data for KPIs such as waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
2
Therefore, an assessment against these defined KPIs cannot be made based on the evidence provided.